Engimmune Therapeutics
Platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on T cell receptor (TCR) targeting solid tumours
Engimmune Therapeutics has raised €16M across 2 funding rounds from 3 investors, most recently a Seed round in May 2022. Based in Basel, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Basel, Switzerland
Total raised
€16M
€15,570,935
Funding rounds
2
Investors
3
distinct backers
Active since
2022-02
latest 2022-05
Funding by year
EUR raised per yearEngimmune Therapeutics — funding by year — interactive chart.
Data table
| Engimmune Therapeutics — funding by year | |
|---|---|
| 2022 | €16M |
Signals
High confidenceRaise-next likelihood9
base rate 44% for Seed
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood9
base rate 11% (2+ rounds)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-05-03 | Seed | €15M | Novo Holdings,Pureos Bioventures | View deal → |
| 2022-02-21 | Other | €481k | BaseLaunch | View deal → |
Related news
- Engimmune Therapeutics raises CHF 15.5 million in seed financingstartupticker.ch · 2022-05
- BaseLaunch invests USD 1.5 million in three new startupsstartupticker.ch · 2022-02
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData